SlideShare uma empresa Scribd logo
1 de 1
Baixar para ler offline
TABLE 2
   Multiple-dose MTX treatment protocol (28, 29).
   Treatment day                                Laboratory evaluation                                        Intervention
   Pretreatment                    hCG, CBC with differential, liver function                Rule out spontaneous Ab
                                     tests, creatinine, blood type and                       Rhogam if Rh negative
                                     antibody screen
   1                               hCG                                                       MTX 1.0 mg/kg IM
   2                                                                                         LEU 0.1 mg/kg IM
   3                               hCG                                                       MTX 1.0 mg/kg IM if <15% decline day
                                                                                                1–day 3
                                                                                             If >15%, stop treatment and start
                                                                                                surveillance
   4                                                                                         LEU 0.1 mg/kg IM
   5                               hCG                                                       MTX 1.0 mg/kg IM if <15% decline day
                                                                                                3–day 5
                                                                                             If >15%, stop treatment and start
                                                                                                surveillance
   6                                                                                         LEU 0.1 mg/kg IM
   7                               hCG                                                       MTX 1.0 mg/kg IM if <15% decline day
                                                                                                5–day 7
                                                                                             If >15%, stop treatment and start
                                                                                                surveillance
   8                                                                                         LEU 0.1 mg/kg IM
   Note: Surveillance every 7 days (until hCG <5 mIU/mL).
   Screening laboratory studies should be repeated 1 week after the last dose of MTX. LEU ¼ leucovorin; IM ¼ intramuscu-
     larly.
   ASRM Practice Commitee. Treatment of ectopic pregnancy. Fertil Steril 2008.


   In both single- and multiple-dose MTX treatment proto-                           When the criteria described earlier are fulfilled, treatment
cols, once hCG levels have met the criteria for initial decline,                 with MTX yields treatment success rates comparable to those
hCG levels are followed serially at weekly intervals to ensure                   achieved with conservative surgery (2, 30, 31). Numerous
that concentrations decline steadily and become undetect-                        open-label studies have been published demonstrating the ef-
able. Complete resolution of an ectopic pregnancy usually                        ficacy of both MTX treatment regimens. One review con-
takes between 2 and 3 weeks but can take as long as 6 to 8                       cluded that MTX treatment was successful in 78%–96% of
weeks when pretreatment hCG levels are in higher ranges                          selected patients. Post-treatment hysterosalpingography
(29, 30, 35). When declining hCG levels again rise, the diag-                    documented tubal patency in 78% of cases; 65% of patients
nosis of a persistent ectopic pregnancy is made.                                 who attempted subsequent pregnancies succeeded, and the

 TABLE 3
   Single-dose MTX treatment protocol (33).
   Treatment day                                          Laboratory evaluation                                      Intervention
   Pretreatment                                         hCG, CBC with differential,                          Rule out spontaneous Ab
                                                          liver function tests,                              Rhogam if Rh negative
                                                          creatinine, blood type
                                                          and antibody screen
   1                                                    hCG                                                  MTX 50 mg/m2 IM
   4                                                    hCG
   7                                                    hCG                                                  MTX 50 mg/m2 IM if b-hCG
                                                                                                              decreased <15%
                                                                                                              between day 4 and day 7
   Note: Surveillance every 7 days (until hCG <5 mIU/mL).
   ASRM Practice Commitee. Treatment of ectopic pregnancy. Fertil Steril 2008.



S208        ASRM Practice Commitee                   Treatment of ectopic pregnancy                             Vol. 90, Suppl 3, November 2008

Mais conteúdo relacionado

Mais procurados

016324s034s035lbl
016324s034s035lbl016324s034s035lbl
016324s034s035lbl
ranju soni
 

Mais procurados (6)

Hormonal therapy breast mine
Hormonal therapy breast mineHormonal therapy breast mine
Hormonal therapy breast mine
 
Tofacitinib
TofacitinibTofacitinib
Tofacitinib
 
Tamoxifen And CYP2D6: Using Pharmacogenetics to discover a new drug
Tamoxifen And CYP2D6:  Using Pharmacogenetics to discover a new drugTamoxifen And CYP2D6:  Using Pharmacogenetics to discover a new drug
Tamoxifen And CYP2D6: Using Pharmacogenetics to discover a new drug
 
Vivitra 150mg injection
Vivitra 150mg injectionVivitra 150mg injection
Vivitra 150mg injection
 
mTORC signaling in myfobroblast diferentiation
mTORC signaling in myfobroblast diferentiationmTORC signaling in myfobroblast diferentiation
mTORC signaling in myfobroblast diferentiation
 
016324s034s035lbl
016324s034s035lbl016324s034s035lbl
016324s034s035lbl
 

Destaque (7)

Exsys travel 54102011144
Exsys travel 54102011144Exsys travel 54102011144
Exsys travel 54102011144
 
Marketing con videos - 5 consejos para hacerlos como un Profesional
Marketing con videos - 5 consejos para hacerlos como un ProfesionalMarketing con videos - 5 consejos para hacerlos como un Profesional
Marketing con videos - 5 consejos para hacerlos como un Profesional
 
GRACIAS, SEÑOR
GRACIAS, SEÑORGRACIAS, SEÑOR
GRACIAS, SEÑOR
 
Material management
Material managementMaterial management
Material management
 
Shangri la slide show
Shangri la slide showShangri la slide show
Shangri la slide show
 
Malca hegemonia española
Malca hegemonia españolaMalca hegemonia española
Malca hegemonia española
 
Domus Academy Alumni sharing
Domus Academy Alumni sharingDomus Academy Alumni sharing
Domus Academy Alumni sharing
 

Semelhante a Medical treatment ectopic

Medical management of ectopic pregnancy
Medical management of ectopic pregnancyMedical management of ectopic pregnancy
Medical management of ectopic pregnancy
dr_sarkar54
 
Gestational trophoblastic neoplesia
Gestational trophoblastic neoplesiaGestational trophoblastic neoplesia
Gestational trophoblastic neoplesia
Mohit Satodia
 
Gentamicin and the Yorkshire-Hartford Regimen
Gentamicin and the Yorkshire-Hartford RegimenGentamicin and the Yorkshire-Hartford Regimen
Gentamicin and the Yorkshire-Hartford Regimen
Kev Frost
 
Methotrexate for optimizing its use in ra 2021 ( ff )
Methotrexate   for optimizing its use in ra 2021 ( ff )Methotrexate   for optimizing its use in ra 2021 ( ff )
Methotrexate for optimizing its use in ra 2021 ( ff )
SafwatElaraby
 
the role of tofac (1)
the role of tofac (1)the role of tofac (1)
the role of tofac (1)
nehal hamdy
 

Semelhante a Medical treatment ectopic (20)

Gtn 1 ppt
Gtn 1 pptGtn 1 ppt
Gtn 1 ppt
 
GESTATIONAL TROPHOBLASTIC NEOPLASIA.pptx
GESTATIONAL TROPHOBLASTIC NEOPLASIA.pptxGESTATIONAL TROPHOBLASTIC NEOPLASIA.pptx
GESTATIONAL TROPHOBLASTIC NEOPLASIA.pptx
 
Medical management of ectopic pregnancy
Medical management of ectopic pregnancyMedical management of ectopic pregnancy
Medical management of ectopic pregnancy
 
GTN
GTNGTN
GTN
 
Gestational trophoblastic neoplesia
Gestational trophoblastic neoplesiaGestational trophoblastic neoplesia
Gestational trophoblastic neoplesia
 
Prostate carcinoma- hormonal therapy 2
Prostate  carcinoma- hormonal therapy 2Prostate  carcinoma- hormonal therapy 2
Prostate carcinoma- hormonal therapy 2
 
Gentamicin and the Yorkshire-Hartford Regimen
Gentamicin and the Yorkshire-Hartford RegimenGentamicin and the Yorkshire-Hartford Regimen
Gentamicin and the Yorkshire-Hartford Regimen
 
Methotrexate for optimizing its use in ra 2021 ( ff )
Methotrexate   for optimizing its use in ra 2021 ( ff )Methotrexate   for optimizing its use in ra 2021 ( ff )
Methotrexate for optimizing its use in ra 2021 ( ff )
 
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
 
the role of tofac (1)
the role of tofac (1)the role of tofac (1)
the role of tofac (1)
 
Gestational trophoblastic disease
Gestational trophoblastic diseaseGestational trophoblastic disease
Gestational trophoblastic disease
 
Adreno Cortical Carcinoma in a Nut Shell
Adreno Cortical Carcinoma in a Nut ShellAdreno Cortical Carcinoma in a Nut Shell
Adreno Cortical Carcinoma in a Nut Shell
 
Ppt ACC follow up
Ppt ACC follow upPpt ACC follow up
Ppt ACC follow up
 
Gentamicin_microteach.ppt
Gentamicin_microteach.pptGentamicin_microteach.ppt
Gentamicin_microteach.ppt
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
 
GOG 240 Bevacizumab in carcinoma cervix
GOG 240 Bevacizumab in carcinoma cervixGOG 240 Bevacizumab in carcinoma cervix
GOG 240 Bevacizumab in carcinoma cervix
 
Mycophenolate Mofetil in Primary Glomerulonephritis
Mycophenolate Mofetil in Primary GlomerulonephritisMycophenolate Mofetil in Primary Glomerulonephritis
Mycophenolate Mofetil in Primary Glomerulonephritis
 
brenutuximab-journal club.pptx
brenutuximab-journal club.pptxbrenutuximab-journal club.pptx
brenutuximab-journal club.pptx
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation Protocols
 
Metronomic chemotherapy in mbc
Metronomic chemotherapy in mbcMetronomic chemotherapy in mbc
Metronomic chemotherapy in mbc
 

Mais de Asha Reddy

Mais de Asha Reddy (20)

LIKELIHOOD RATIOS -Agathokleous 2013 Meta-analysis 2nd trimester T 21.
LIKELIHOOD RATIOS -Agathokleous 2013 Meta-analysis 2nd trimester T 21.LIKELIHOOD RATIOS -Agathokleous 2013 Meta-analysis 2nd trimester T 21.
LIKELIHOOD RATIOS -Agathokleous 2013 Meta-analysis 2nd trimester T 21.
 
Dindigul district cervical screening study, india acceptability, effectivenes...
Dindigul district cervical screening study, india acceptability, effectivenes...Dindigul district cervical screening study, india acceptability, effectivenes...
Dindigul district cervical screening study, india acceptability, effectivenes...
 
Visual inspection with Lugol’s iodine
 Visual inspection with Lugol’s iodine Visual inspection with Lugol’s iodine
Visual inspection with Lugol’s iodine
 
cfDNA Screening for Fetal Aneuploidy- Positive predictive value
cfDNA Screening for Fetal Aneuploidy- Positive predictive valuecfDNA Screening for Fetal Aneuploidy- Positive predictive value
cfDNA Screening for Fetal Aneuploidy- Positive predictive value
 
SMFM : clarification of recommendations for cfDNA screening
SMFM : clarification of recommendations for cfDNA screeningSMFM : clarification of recommendations for cfDNA screening
SMFM : clarification of recommendations for cfDNA screening
 
Discordant noninvasive prenatal testing & cytogenetic results: 109 consecutiv...
Discordant noninvasive prenatal testing & cytogenetic results: 109 consecutiv...Discordant noninvasive prenatal testing & cytogenetic results: 109 consecutiv...
Discordant noninvasive prenatal testing & cytogenetic results: 109 consecutiv...
 
Repeated failed non-invasive prenatal testing in autoimmune disease owing to...
Repeated failed non-invasive prenatal testing in  autoimmune disease owing to...Repeated failed non-invasive prenatal testing in  autoimmune disease owing to...
Repeated failed non-invasive prenatal testing in autoimmune disease owing to...
 
A case of repeated failed non-invasive prenatal testing in a woman with immun...
A case of repeated failed non-invasive prenatal testing in a woman with immun...A case of repeated failed non-invasive prenatal testing in a woman with immun...
A case of repeated failed non-invasive prenatal testing in a woman with immun...
 
Recurrent Third-Trimester Fetal Loss and Maternal Mosaicism for Long-QT Syndrome
Recurrent Third-Trimester Fetal Loss and Maternal Mosaicism for Long-QT SyndromeRecurrent Third-Trimester Fetal Loss and Maternal Mosaicism for Long-QT Syndrome
Recurrent Third-Trimester Fetal Loss and Maternal Mosaicism for Long-QT Syndrome
 
Fetal orbital diameter (mm)- gestational age
Fetal orbital diameter (mm)- gestational ageFetal orbital diameter (mm)- gestational age
Fetal orbital diameter (mm)- gestational age
 
Recurrent NIHF Hydrops Investigations
Recurrent NIHF Hydrops InvestigationsRecurrent NIHF Hydrops Investigations
Recurrent NIHF Hydrops Investigations
 
POF/ Primary Ovarian Insufficiency/ POI -Causes
POF/ Primary Ovarian Insufficiency/ POI -CausesPOF/ Primary Ovarian Insufficiency/ POI -Causes
POF/ Primary Ovarian Insufficiency/ POI -Causes
 
Antiphospholipid syndrome - ACOG 2015 Recommendations for Heparin
Antiphospholipid syndrome - ACOG 2015 Recommendations for HeparinAntiphospholipid syndrome - ACOG 2015 Recommendations for Heparin
Antiphospholipid syndrome - ACOG 2015 Recommendations for Heparin
 
Recommended Thromboprophylaxis for Pregnancies Complicated by Inherited Throm...
Recommended Thromboprophylaxis for Pregnancies Complicated by Inherited Throm...Recommended Thromboprophylaxis for Pregnancies Complicated by Inherited Throm...
Recommended Thromboprophylaxis for Pregnancies Complicated by Inherited Throm...
 
Markers for endometriosis
Markers for endometriosisMarkers for endometriosis
Markers for endometriosis
 
Conventional Units to SI units conversion table
Conventional Units to SI units conversion  table Conventional Units to SI units conversion  table
Conventional Units to SI units conversion table
 
Nifty
NiftyNifty
Nifty
 
Expressed breast milk on refrigerator storage
Expressed breast milk on refrigerator storageExpressed breast milk on refrigerator storage
Expressed breast milk on refrigerator storage
 
Human Milk Banking Guidelines -INDIAN ACADEMY OF PEDIATRICS
Human Milk Banking Guidelines  -INDIAN ACADEMY OF PEDIATRICSHuman Milk Banking Guidelines  -INDIAN ACADEMY OF PEDIATRICS
Human Milk Banking Guidelines -INDIAN ACADEMY OF PEDIATRICS
 
Suture ligation of supernumerary digits and tags :An outmoded practice
Suture ligation of supernumerary digits and tags :An outmoded practiceSuture ligation of supernumerary digits and tags :An outmoded practice
Suture ligation of supernumerary digits and tags :An outmoded practice
 

Medical treatment ectopic

  • 1. TABLE 2 Multiple-dose MTX treatment protocol (28, 29). Treatment day Laboratory evaluation Intervention Pretreatment hCG, CBC with differential, liver function Rule out spontaneous Ab tests, creatinine, blood type and Rhogam if Rh negative antibody screen 1 hCG MTX 1.0 mg/kg IM 2 LEU 0.1 mg/kg IM 3 hCG MTX 1.0 mg/kg IM if <15% decline day 1–day 3 If >15%, stop treatment and start surveillance 4 LEU 0.1 mg/kg IM 5 hCG MTX 1.0 mg/kg IM if <15% decline day 3–day 5 If >15%, stop treatment and start surveillance 6 LEU 0.1 mg/kg IM 7 hCG MTX 1.0 mg/kg IM if <15% decline day 5–day 7 If >15%, stop treatment and start surveillance 8 LEU 0.1 mg/kg IM Note: Surveillance every 7 days (until hCG <5 mIU/mL). Screening laboratory studies should be repeated 1 week after the last dose of MTX. LEU ¼ leucovorin; IM ¼ intramuscu- larly. ASRM Practice Commitee. Treatment of ectopic pregnancy. Fertil Steril 2008. In both single- and multiple-dose MTX treatment proto- When the criteria described earlier are fulfilled, treatment cols, once hCG levels have met the criteria for initial decline, with MTX yields treatment success rates comparable to those hCG levels are followed serially at weekly intervals to ensure achieved with conservative surgery (2, 30, 31). Numerous that concentrations decline steadily and become undetect- open-label studies have been published demonstrating the ef- able. Complete resolution of an ectopic pregnancy usually ficacy of both MTX treatment regimens. One review con- takes between 2 and 3 weeks but can take as long as 6 to 8 cluded that MTX treatment was successful in 78%–96% of weeks when pretreatment hCG levels are in higher ranges selected patients. Post-treatment hysterosalpingography (29, 30, 35). When declining hCG levels again rise, the diag- documented tubal patency in 78% of cases; 65% of patients nosis of a persistent ectopic pregnancy is made. who attempted subsequent pregnancies succeeded, and the TABLE 3 Single-dose MTX treatment protocol (33). Treatment day Laboratory evaluation Intervention Pretreatment hCG, CBC with differential, Rule out spontaneous Ab liver function tests, Rhogam if Rh negative creatinine, blood type and antibody screen 1 hCG MTX 50 mg/m2 IM 4 hCG 7 hCG MTX 50 mg/m2 IM if b-hCG decreased <15% between day 4 and day 7 Note: Surveillance every 7 days (until hCG <5 mIU/mL). ASRM Practice Commitee. Treatment of ectopic pregnancy. Fertil Steril 2008. S208 ASRM Practice Commitee Treatment of ectopic pregnancy Vol. 90, Suppl 3, November 2008